Compare Nuvation Bio Inc. Class A Common Stock (NUVB) vs RLX Technology Inc (RLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuvation Bio Inc. Class A Common Stock vs RLX Technology Inc — how do they compare? Nuvation Bio Inc. Class A Common Stock trades at $4.95 (market cap $1.71B), while RLX Technology Inc trades at $1.73 (market cap $2.11B). The key difference: RLX Technology Inc is the larger of the two by market cap, and RLX Technology Inc pays a 5.78% dividend while Nuvation Bio Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nuvation Bio Inc. Class A Common Stock for 0 Days and RLX Technology Inc for 34 Days on average.
| NUVB | RLX | |
|---|---|---|
Market Cap | $1.71B | $2.11B |
Volume | 5,448,712 | 621,808 |
Sector | Health | Consumer Staples |
52-Week High | $9.54 | $2.57 |
52-Week Low | $3.41 | $1.68 |
Typical Hold Time | 0 Days | 34 Days |
Enterprise Value | $1.30B | $844.50M |
Dividend Yield | — | 5.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
RLX Technology trades at $1.73, down 1.76% with a bearish technical signal. The stock recently hit 52-week lows amid margin compression despite 14.8% revenue growth in Q2 2026. Valuation appears reasonable with P/E of 15.55 and P/B below 1, but earnings misses in recent quarters raise execution concerns. International expansion now drives 70% of revenue following European acquisitions.
The outlook remains challenged by consecutive earnings misses and technical weakness, though discounted valuation and international growth provide potential upside. Key risks include sustained margin pressure and integration challenges from recent acquisitions. With only one analyst covering and maintaining a hold rating, institutional conviction appears limited.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Nuvation Bio Inc. Class A Common Stock
Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →
